Subscribe to RSS
DOI: 10.1055/s-2006-960774
© Georg Thieme Verlag Stuttgart · New York
The Effects of Tetramethylpyrazine on the Incidence of Arrhythmias and the Release of PGI2 and TXA2 in the Ischemic Rat Heart
Publication History
1998
1998
Publication Date:
04 January 2007 (online)
Abstract
Pretreatment with tetramethylpyrazine (TMP, 12 mg/kg/day), a drug originally derived from the rhizomes of Ligusticum wallichii, significantly reduced the incidence of ischemia-induced ventricular tachycardia (VT) and fibrillation (VF) from 100% and 50% of control hearts to 41% (p < 0.05) and 0% (p < 0.05), respectively, in the ischemic rat heart. TMP also diminished the incidence of reperfusion-induced VT and VF from 100% and 100% of control hearts to 33% (p < 0.05) and 41% (p < 0.05), respectively. Pretreatment with TMP produced a slight, but significant increase of 6-keto-PGF1α and a decrease of TXB2 production during aerobic perfusion. Ischemia and reperfusion markedly increased the release of 6-keto-PGF1α and TXB2. Pretreatment with TMP significantly enhanced the release of 6-keto-PGF1α and diminished TXB2 outflow following left coronary artery occlusion and reperfusion.